Overview
- Grifols said it is preparing a public share sale of a minority stake in its US Biopharma business to raise cash for debt reduction and investment in growth.
- The company has not disclosed valuation, stake size, or final terms, and it plans a separate governance structure for the US-listed unit.
- Biopharma produced €6.487 billion of the group’s €7.524 billion in 2025 revenue, and Grifols reported €402 million in net profit for the year.
- El Periódico, citing sector sources, reported a potential €23–27 billion valuation for the unit, while Bloomberg reported an aim to float about 20 percent at roughly €6 billion, highlighting uncertainty around pricing.
- Grifols says a US float aligns with the world’s largest plasma market, which supplies over 60 percent of global plasma and favors scaled players due to strict regulations and high entry costs.